본문 바로가기

Preventive and therapeutic effects of a super-multivalent sialylated filamentous bacteriophage against the influenza virus

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
BIOMATERIALS312 · 2025
피인용
Web of Science 8Scopus 9
FWCI (Scopus)
1.67
JCR IF
JCR 2024 12.9
ISSN
0142-9612

저자

  1. Chung, Jinhyo제1저자Sungkyunkwan Univ, Dept Integrat Biotechnol, Suwon 16419, South Korea
  2. 김세훈Pusan Natl Univ, BIOIT Foundry Technol Inst, Busan 46241, South Korea
  3. Jeong, JiyoonSungkyunkwan Univ, Dept Integrat Biotechnol, Suwon 16419, South Korea
  4. Kim, DoyeonSungkyunkwan Univ, Dept Integrat Biotechnol, Suwon 16419, South Korea
  5. 조안나Pusan Natl Univ, BIOIT Foundry Technol Inst, Busan 46241, South Korea
  6. 김화영Pusan Natl Univ, BIOIT Foundry Technol Inst, Busan 46241, South Korea
  7. Hwang, JaehyeonSungkyunkwan Univ, Dept Integrat Biotechnol, Suwon 16419, South Korea
  8. Kweon, Dae-HyukSungkyunkwan Univ, Dept Integrat Biotechnol, Suwon 16419, South Korea
  9. 유소영교신저자Pusan Natl Univ, BIOIT Foundry Technol Inst, Busan 46241, South Korea
  10. Chung, Woo-Jae교신저자Sungkyunkwan Univ, Dept Integrat Biotechnol, Suwon 16419, South Korea

초록

The resurgence of influenza viruses as a significant global threat emphasizes the urgent need for innovative antiviral strategies beyond existing treatments. Here, we present the development and evaluation of a novel super-multivalent sialyllactosylated filamentous phage, termed t-6SLPhage, as a potent entry blocker for influenza A viruses. Structural variations in sialyllactosyl ligands, including linkage type, valency, net charge, and spacer length, were systematically explored to identify optimal binding characteristics against target hemagglutinins and influenza viruses. The selected SLPhage equipped with optimal ligands, exhibited exceptional inhibitory potency in in vitro infection inhibition assays. Furthermore, in vivo studies demonstrated its efficacy as both a preventive and therapeutic intervention, even when administered post-exposure at 2 days post-infection, under 4 lethal dose 50% conditions. Remarkably, co-administration with oseltamivir revealed a synergistic effect, suggesting potential combination therapies to enhance efficacy and mitigate resistance. Our findings highlight the efficacy and safety of sialylated filamentous bacteriophages as promising influenza inhibitors. Moreover, the versatility of M13 phages for surface modifications offers avenues for further engineering to enhance therapeutic and preventive performance.

키워드

Combination therapyEntry blockerFilamentous bacteriophageIn vivo therapeutic effectInfluenza A virusSialyllactoseRECEPTOR-BINDINGM13 BACTERIOPHAGEIN-VITROAFFINITYOLIGOSACCHARIDESHEMAGGLUTININNUCLEOPROTEININHIBITIONCOMPLEMENTANALOGS

식별자

Scopus EID
2-s2.0-85200633670
WoS UID
001292379700001